Intra-Cellular Therapies Reports Third Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Piper Remains Constructive on Intra-Cellular Therapies (ITCI) Following Q3 Report; Affirms at 'Overweight'
November 9, 2016 12:39 PM ESTPiper Jaffray affirms Intra-Cellular Therapies (Nasdaq: ITCI) with an Overweight rating and $22 price target following Q3 results and update issued earlier Wednesday.
Analyst Charles Duncan noted the following: It ended 3Q16 with $413M in cash available for operations, which should fund the... More
Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 14c
November 9, 2016 7:06 AM ESTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.70), $0.14 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.36 thousand versus the consensus estimate of $50 thousand.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
... More